

Synopsys Inc. (SNPS)

Nasdaq; business equipment; SIC 7372, Services-Prepackaged Software; CIK 0000883241

Synopsys Inc.
SNPS; business equipment

Grade

D

A

B

C

D

E

fourth fifth of 497 graded peers
percentile 77.2; sampling error 2.2 points; lower is stronger

Rank

384 of 497

Profitability

D

percentile 63.7

Solvency

C

percentile 56.2

Growth and financing

C

percentile 56.7

Reliability

0.94 AUC
filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025

Peer failure rate

0.52% a year
Item 1.03 bankruptcies, same asset band, 2012 to 2025

Size band

over \$2.67B assets
total assets \$48.2B

Standard universe

inside
revenue above \$1M and assets above \$10M

Warnings

none active

Inputs computable

12 of 14

Graded from

filings received through Dec 22, 2025
291 days before the rescans; latest periodic filing 10-Q received Aug 26, 2026

Last close

\$497.97
2026-10-08; market equity \$95.4B

Price used in grade

None



D, the sloth

fourth fifth of its sector; letters are fifths of the 497 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D/E from Apr 21, 2026, E from May 21, 2026, D/E from Jul 21, 2026, D from Aug 26, 2026

Letter at every rescanscan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

Business, in the company's words

opening of Item 1 of the 10-K received Dec 22, 2025

Synopsys, Inc. (Synopsys, we, our or us) is the leader in engineering solutions from silicon to systems, enabling customers to rapidly innovate AI-powered products. We deliver trusted and comprehensive solutions spanning silicon design, silicon intellectual property (IP), simulation and analysis (S&A) as well as design services. We partner closely with our customers across a wide range of industries to maximize their R&D capability and productivity, powering innovation today that ignites the ingenuity of tomorrow.

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Assay SNPS, as of Oct 9, 2026, page 1


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 63.7						
Gross profitability		11.3%	28.5%	81.1	558	2025-10-31
Return on invested capital		not computable	10.9%			a prior annual debt, equity, and cash observation is required
Accruals ratio		(0.6%)	(7.4%)	84.2	621	2025-10-31
Gross margin stability, five years		1.3 pts	2.4 pts	25.7	429	2025-10-31
Solvency, sleeve percentile 56.2						
Twelve-month failure probability		0.04%	0.05%	32.0	101	2026-07-31
Altman Z double-prime		2.63	2.18	40.2	566	2025-10-31
Net debt to EBITDA		6.73x	1.11x	92.5	147	2025-10-31
Interest coverage		not computable	3.77x			latest aligned inputs end 2023-10-31; latest annual assets end 2025-10-31
Current ratio		1.62x	2.02x	60.0	666	2025-10-31
Growth and financing, sleeve percentile 56.7						
Revenue growth, three-year compound		15.2%	6.4%	25.7	538	2025-10-31
Free cash flow growth, three-year compound		(5.6%)	17.2%	82.0	268	2025-10-31
Reinvestment rate		(230.1%)	14.3%	84.9	226	2025-10-31
Asset growth, three years		72.4%	5.0%	3.9	563	2025-10-31
Net share issuance, one year		23.8%	0.5%	86.9	407	2025-12-15

Among 497 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
379	Coherent Corp. (COHR)	76.2	D	dilution
380	C3.ai, Inc. (AI)	76.4	D	
381	Airgain Inc. (AIRG)	76.6	D	
382	Marchex Inc. (MCHX)	76.8	D	
383	Harvard Bioscience Inc. (HBIO)	77.0	D	
384	Synopsys Inc. (SNPS) <	77.2	D	
385	Duos Technologies Group, Inc. (DUOT)	77.4	D	dilution, late filer, fortress balance sheet
386	Spectrum Brands Holdings, Inc. (SPB)	77.6	D	
387	GoodRx Holdings, Inc. (GDRX)	77.8	D/E	
388	Thermo Fisher Scientific Inc. (TMO)	78.0	D/E	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(10.9%)	2.2%	40
Distance from 52-week high	(6.9%)	(30.0%)	84
EBIT to enterprise value	0.9%	1.5%	45
Free cash flow yield	1.4%	2.7%	36
Book value to price	0.33	0.23	58
Sales to price	0.07	0.30	15
Composite equity issuance, five years	22.5%	3.9%	74
Relative strength against the sector, log excess return	(0.40)	(0.26)	40

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 3 of 9, period end 2025-10-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$3.6B
Operating cash flow, four quarters	\$2.9B
Months of runway	not finite
Days since last periodic filing	44 (10-Q received Aug 26, 2026)
Median daily dollar volume, 63 sessions	\$703.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$5.4B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
2	assets	us-gaap:Assets	\$48.2B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
3	operating income	us-gaap:OperatingIncomeLoss	\$914.9M	2025-10-31	2025-12-22	10-K	0000883241-25-000028
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$14.4B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$56.0M	2025-10-31	2025-12-22	10-K	0000883241-25-000028
6	total debt	us-gaap:LongTermDebt	\$13.5B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
7	book equity	us-gaap:StockholdersEquity	\$28.3B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$2.9B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
9	net income	us-gaap:NetIncomeLoss	\$1.3B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.5B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
11	assets	us-gaap:Assets	\$13.1B	2024-10-31	2025-12-22	10-K	0000883241-25-000028
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$7.1B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
13	gross profit	us-gaap:GrossProfit	\$4.9B	2024-10-31	2025-12-22	10-K	0000883241-25-000028
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$6.1B	2024-10-31	2025-12-22	10-K	0000883241-25-000028
15	gross profit	us-gaap:GrossProfit	\$4.3B	2023-10-31	2025-12-22	10-K	0000883241-25-000028
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$5.3B	2023-10-31	2025-12-22	10-K	0000883241-25-000028
17	gross profit	us-gaap:GrossProfit	\$3.7B	2022-10-31	2024-12-19	10-K	0000883241-24-000024
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$4.6B	2022-10-31	2024-12-19	10-K	0000883241-24-000024
19	gross profit	us-gaap:GrossProfit	\$3.3B	2021-10-31	2023-12-12	10-K	0000883241-23-000019
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$4.2B	2021-10-31	2023-12-12	10-K	0000883241-23-000019
21	current assets	us-gaap:AssetsCurrent	\$6.0B	2025-10-31	2025-12-22	10-K	0000883241-25-000028

22	current liabilities	us-gaap:LiabilitiesCurrent	\$3.7B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
23	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$10.3B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
24	liabilities	us-gaap:Liabilities	\$19.9B	2025-10-31	2025-12-22	10-K	0000883241-25-000028
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$660.4M	2025-10-31	2025-12-22	10-K	0000883241-25-000028
26	operating income	us-gaap:OperatingIncomeLoss	\$1.3B	2023-10-31	2025-12-22	10-K	0000883241-25-000028
27	interest expense	us-gaap:InterestExpense	\$1.2M	2023-10-31	2023-12-12	10-K	0000883241-23-000019
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$169.5M	2025-10-31	2025-12-22	10-K	0000883241-25-000028
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.4B	2024-10-31	2025-12-22	10-K	0000883241-25-000028
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$139.5M	2024-10-31	2025-12-22	10-K	0000883241-25-000028
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.7B	2023-10-31	2025-12-22	10-K	0000883241-25-000028
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$189.6M	2023-10-31	2025-12-22	10-K	0000883241-25-000028
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.7B	2022-10-31	2024-12-19	10-K	0000883241-24-000024
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$136.6M	2022-10-31	2024-12-19	10-K	0000883241-24-000024
35	current assets	us-gaap:AssetsCurrent	\$6.5B	2024-10-31	2025-12-22	10-K	0000883241-25-000028
36	current liabilities	us-gaap:LiabilitiesCurrent	\$2.7B	2024-10-31	2025-12-22	10-K	0000883241-25-000028
37	assets	us-gaap:Assets	\$10.3B	2023-10-31	2024-12-19	10-K	0000883241-24-000024
38	assets	us-gaap:Assets	\$9.4B	2022-10-31	2023-12-12	10-K	0000883241-23-000019
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	191,318,206	2025-12-15	2025-12-22	10-K	0000883241-25-000028
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	154,578,449	2024-12-16	2024-12-19	10-K	0000883241-24-000024